Neon Therapeutics Inc (NASDAQ:NTGN) – Equities research analysts at Oppenheimer lowered their Q1 2019 earnings estimates for shares of Neon Therapeutics in a research report issued to clients and investors on Monday, March 11th. Oppenheimer analyst L. Cann now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their prior forecast of ($0.80). Oppenheimer also issued estimates for Neon Therapeutics’ Q2 2019 earnings at ($0.85) EPS, Q3 2019 earnings at ($0.88) EPS, Q4 2019 earnings at ($0.92) EPS, FY2019 earnings at ($3.47) EPS, Q1 2020 earnings at ($0.89) EPS, Q2 2020 earnings at ($0.99) EPS, Q3 2020 earnings at ($1.18) EPS, Q4 2020 earnings at ($1.27) EPS and FY2020 earnings at ($4.32) EPS.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.11).
Shares of NTGN opened at $5.61 on Thursday. Neon Therapeutics has a 52 week low of $4.20 and a 52 week high of $16.23. The company has a market capitalization of $168.56 million and a PE ratio of -1.01.
Several institutional investors and hedge funds have recently modified their holdings of NTGN. Northern Trust Corp purchased a new position in Neon Therapeutics in the 2nd quarter worth approximately $137,000. Bank of New York Mellon Corp purchased a new stake in Neon Therapeutics during the 3rd quarter valued at $141,000. Bank of America Corp DE raised its stake in Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after buying an additional 6,493 shares during the last quarter. Geode Capital Management LLC raised its stake in Neon Therapeutics by 127.0% during the 4th quarter. Geode Capital Management LLC now owns 60,309 shares of the company’s stock valued at $303,000 after buying an additional 33,741 shares during the last quarter. Finally, Vanguard Group Inc raised its stake in Neon Therapeutics by 215.9% during the 3rd quarter. Vanguard Group Inc now owns 197,414 shares of the company’s stock valued at $1,686,000 after buying an additional 134,914 shares during the last quarter. 72.08% of the stock is currently owned by hedge funds and other institutional investors.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Recommended Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.